Abstract
Background: In addition to national policies and interventions, certain regions in England (particularly in the North) coordinate regional tobacco control programmes. This study examined trends in tobacco smoking prevalence and socioeconomic inequalities in smoking across regions. Methods: Data were obtained from monthly household surveys of adults (≥16y) in England, conducted between November 2006 and July 2024 (total n=368,057). We used logistic regression to estimate time trends in current smoking by region, and tested interactions with occupational social grade to explore differences between more and less advantaged groups. Results: Smoking prevalence declined most in the North (28.8% to 15.8%; -12.9 percentage points [95%CI -14.4; -11.5]), similar to the national average in the Midlands (25.2% to 16.0%; -9.2 [-10.6; -7.9]), and least in the South (22.7% to 17.3%; -5.3 [-6.5; -4.0]), reducing regional disparities such that prevalence was similar across regions in 2024. Socioeconomic inequalities in smoking prevalence between more and less advantaged social grades fell most in Yorkshire and the Humber (from 17.9 percentage points [14.1; 21.8] to 3.7 [0.4; 7.0]) and the West Midlands (from 16.1 [12.8; 19.6] to 3.0 [-0.03; 6.0]). Regions with sustained regional tobacco control activity saw greater declines in smoking prevalence (-18.1 [-21.4; -14.7]) than regions with none (-12.8 [-13.9; -11.6]). Conclusions: Between 2006 and 2024, smoking rates in the North of England fell faster than the national average, aligning with other regions. Regional tobacco control programmes appeared to contribute to this progress.
Competing Interest Statement
JB has received unrestricted research funding from Pfizer and J&J, who manufacture smoking cessation medications. LS has received honoraria for talks, unrestricted research grants and travel expenses to attend meetings and workshops from manufactures of smoking cessation medications (Pfizer; J&J), and has acted as paid reviewer for grant awarding bodies and as a paid consultant for health care companies. All authors declare no financial links with tobacco companies, e-cigarette manufacturers, or their representatives.
Clinical Protocols
Funding Statement
This work was supported by Cancer Research UK (PRCRPG-Nov21\100002).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the STS was granted originally by the UCL Ethics Committee (ID 0498/001). The data are not collected by UCL and are anonymised when received by UCL.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data analysed in the present study are available upon reasonable request to the authors
